The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
ConditionAging
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21+
SponsorState University of New York at Buffalo
About this trial
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Eligibility criteria
Qualifiers
Both sexes
Have not been vaccinated with any licensed or experimental pneumococcal vaccine
Ages 21-40; and ≥65. Individuals >60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
Free of acute infections within the last 2 weeks
Disqualifiers
Previous vaccination with any licensed or experimental pneumococcal vaccine
Known hypersensitivity to vaccination and vaccine components
Immune deficiency
Use of immune-modulating or suppressive drugs
Trial design
Treatments tested in this trial
- vaccine
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
State University of New York at Buffalo
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov